Eli Lilly and Co (LLY)

Industry Drug Manufacturers - General

This stock can be held in an Investment ISA and an Investment Account

Sell

$923.18

Buy

$924.90

arrow-up$33.14 (+3.74%)

Prices updated at 31 Mar 2026, 11:22 EDT

Prices minimum 15 mins delay

Prices in USD

Eli Lilly and Co is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. It discovers, develops, manufactures, and sells human pharmaceutical products and animal health products.

S&P 500

2.91%

NYSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Income statement

Year chevron-l-regular chevron-r-regular	2024	2025
	45,043m	65,179m
	36,625m	54,127m
	17,040m	29,696m
	37.83	45.56
	10,590m	20,640m
	18,807m	31,693m
Sales, General and administrative	8,594m	11,094m
Interest expenses	-	-
Provision for income taxes	2,090m	5,091m
Operating expenses	19,585m	24,431m
Income before taxes	12,680m	25,731m
Net income available to common shareholders	10,590m	20,640m
	11.76	23
Net interest income	-	-
Advertising and promotion	-	-
Net investment income, net	-	-
Realised capital gains (losses), net	-	-
Total benefits, claims and expenses	-	-
Earnings per share (diluted)	11.71	22.95
Free cash flow per share	-2.5162	7.1473
Book value/share	15.8656	26.5906
Debt equity ratio	1.998809	1.540155

Balance sheet

Year chevron-l-regular chevron-r-regular	2024	2025
Current assets	32,740m	55,629m
Current liabilities	28,377m	35,228m
Total capital	42,719m	67,403m
Total debt	33,644m	42,503m
Total equity	14,192m	26,535m
Total non current liabilities	-	-
Loans	28,527m	40,868m
Total assets	78,715m	112,476m
Total liabilities	-	-
Cash and cash equivalents	3,268m	7,268m
Common stock	898m	895m

Cash flow

Year chevron-l-regular chevron-r-regular	2024	2025
Cash at beginning of period	2,819m	3,268m
Cash dividends paid	-4,680m	-5,384m
	414m	5,964m
Investments (gains) losses	-9,301m	-10,972m
	3,268m	7,268m
Net income	-	-
	8,818m	16,813m
	-8,404m	-10,849m

The figures shown in the tables are quoted in the currency of the stock selected.

Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.